First experiences with 177Lu-PSMA-617 therapy for recurrent or metastatic salivary gland cancer

被引：0
|
作者：
Thomas J. W. Klein Nulent
Robert J. J. van Es
Stefan M. Willems
Arthur. J. A. T. Braat
Lot A. Devriese
Remco de Bree
Bart de Keizer
机构：
[1] University Medical Center Utrecht,Department of Head and Neck Surgical Oncology
[2] University Medical Center Utrecht,Department of Oral and Maxillofacial Surgery
[3] University Medical Center Utrecht,Department of Pathology
[4] University Medical Center Groningen,Department of Pathology and Medical Biology
[5] University Medical Center Utrecht,Department of Radiology and Nuclear Medicine
[6] University Medical Center Utrecht,Department of Medical Oncology
来源：
EJNMMI Research | / 11卷
关键词：
Lutetium; Positron-emission tomography; Radionuclide; Adenoid cystic carcinoma; Salivary gland cancer;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [41] 177Lu-PSMA radioligand therapy for recurrent/metastatic salivary gland cancer patients, a phase II pilot study
    Uijen, M. J. M.
    Gotthardt, M.
    Nagarajah, J.
    Van Herpen, C. M. L.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2022, 49 (SUPPL 1) : S249 - S250
  • [42] 177Lu-PSMA-617 Radioligand Therapy in Patient With Prostate Cancer Sciatic Nerve Metastasis
    Tonnelet, David
    Edet-Sanson, Agathe
    Augusto, Laetitia
    Cabourg, Marine
    Thureau, Sebastien
    CLINICAL NUCLEAR MEDICINE, 2024, 49 (12) : E668 - E669
  • [43] Hematotoxicity after Radioligand Therapy with 177Lu-PSMA-617 in Patients with Metastastic Prostate Cancer
    Groener, Daniel
    Baumgarten, Justus
    Davis, Karen
    Happel, Christian
    Ngoc, Christina Nguyen
    Wichert, Jennifer
    Mader, Nicolai
    Mandel, Philipp
    Nikolaos, Tselis
    Gruenwald, Frank
    Sabet, Amir
    JOURNAL OF NUCLEAR MEDICINE, 2020, 61
  • [44] Establishing 177Lu-PSMA-617 Radioligand Therapy in a Syngeneic Model of Murine Prostate Cancer
    Fendler, Wolfgang P.
    Stuparu, Andreea D.
    Evans-Axelsson, Susan
    Luckerath, Katharina
    Wei, Liu
    Kim, Woosuk
    Poddar, Soumya
    Said, Jonathan
    Radu, Caius G.
    Eiber, Matthias
    Czernin, Johannes
    Slavik, Roger
    Herrmann, Ken
    JOURNAL OF NUCLEAR MEDICINE, 2017, 58 (11) : 1786 - 1792
  • [45] 177Lu-PSMA-617 radioligand therapy of mCRPC: evaluation criteria of response
    Rahbar, Kambiz
    Boegemann, Martin
    Ahmadzadehfar, Hojjat
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2017, 44 (01) : 166 - 167
  • [46] 177Lu-PSMA-617 radioligand therapy of mCRPC: evaluation criteria of response
    Kambiz Rahbar
    Martin Bögemann
    Hojjat Ahmadzadehfar
    European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44 : 166 - 167
  • [47] VISION trial: 177Lu-PSMA-617 for progressive metastatic castration-resistant prostate cancer
    Rohith, Gorrepati
    INDIAN JOURNAL OF UROLOGY, 2021, 37 (04) : 372 - 373
  • [48] 177Lu-PSMA-617 Treatment of Metastatic Castration-Resistant Prostate Cancer: Efficacy and Survival
    Demirci, E.
    Akyel, R.
    Sahin, O.
    Ocak, M.
    Aygun, A.
    Pehlivanoglu, H.
    Karayel, E.
    Kabasakal, L.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2017, 44 : S202 - S203
  • [49] Initial Experience with 177Lu-PSMA-617 Therapy: Toxicity and Outcomes PostApproval
    Tuchayi, Abuzar Moradi
    Kim, Sarasa
    Morley, Amanda
    Saelee, Rachelle
    Wang, Yingbing
    Heath, Courtney Lawhn
    Juarez, Roxanna
    Hope, Thomas
    JOURNAL OF NUCLEAR MEDICINE, 2023, 64
  • [50] Prostate Cancer Treatment: 177Lu-PSMA-617 Considerations, Concepts, and Limitations
    Sartor, Oliver
    Herrmann, Ken
    JOURNAL OF NUCLEAR MEDICINE, 2022, 63 (06) : 823 - 829
12345